{"id":"NCT02712320","sponsor":"Foresee Pharmaceuticals Co., Ltd.","briefTitle":"Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg","officialTitle":"An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02","primaryCompletion":"2017-05","completion":"2017-12-19","firstPosted":"2016-03-18","resultsPosted":"2018-09-12","lastUpdate":"2019-03-26"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms"],"interventions":[{"type":"DRUG","name":"LMIS 50 mg","otherNames":[]}],"arms":[{"label":"LMIS 50 mg","type":"EXPERIMENTAL"}],"summary":"This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Up to 48 weeks","effectByArm":[{"arm":"LMIS 50 mg","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":30},"commonTop":["Fatigue","Hypertension"]}}